DE602006021283D1 - Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert - Google Patents

Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert

Info

Publication number
DE602006021283D1
DE602006021283D1 DE602006021283T DE602006021283T DE602006021283D1 DE 602006021283 D1 DE602006021283 D1 DE 602006021283D1 DE 602006021283 T DE602006021283 T DE 602006021283T DE 602006021283 T DE602006021283 T DE 602006021283T DE 602006021283 D1 DE602006021283 D1 DE 602006021283D1
Authority
DE
Germany
Prior art keywords
lung cancer
peptide vaccine
cancer expressing
ttk polypeptide
expressing ttk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021283T
Other languages
English (en)
Inventor
Takuya Tsunoda
Hideaki Tahara
Shuichi Nakatsuru
Yataro Daigo
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of DE602006021283D1 publication Critical patent/DE602006021283D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006021283T 2005-02-25 2006-02-17 Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert Active DE602006021283D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65685705P 2005-02-25 2005-02-25
PCT/JP2006/303354 WO2006090810A2 (en) 2005-02-25 2006-02-17 Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides

Publications (1)

Publication Number Publication Date
DE602006021283D1 true DE602006021283D1 (de) 2011-05-26

Family

ID=36570330

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021283T Active DE602006021283D1 (de) 2005-02-25 2006-02-17 Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert

Country Status (10)

Country Link
US (2) US7847060B2 (de)
EP (3) EP2325306B1 (de)
JP (5) JP4461179B2 (de)
DE (1) DE602006021283D1 (de)
DK (2) DK2325306T3 (de)
ES (3) ES2364670T3 (de)
HK (2) HK1156076A1 (de)
PL (2) PL2325305T3 (de)
PT (2) PT2325305E (de)
WO (1) WO2006090810A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TW200831673A (en) * 2006-12-13 2008-08-01 Oncotherapy Science Inc TTK as tumor marker and therapeutic target for lung cancer
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
AU2012261723B2 (en) * 2007-02-21 2014-11-27 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing tumor-associated antigens
EP2185732A1 (de) * 2007-07-30 2010-05-19 Oncotherapy Science, Inc. Mit krebs assoziiertes gen ly6k
MX2010002018A (es) 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
RU2532105C2 (ru) 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
KR20110117112A (ko) 2008-12-24 2011-10-26 온코세라피 사이언스 가부시키가이샤 Ｃ１ｏｒｆ５９ 펩티드 및 이를 포함하는 백신
AU2010219951A1 (en) * 2009-03-04 2011-08-25 Oncotherapy Science, Inc. VANGL1 peptides and vaccines including the same
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
ES2662325T3 (es) 2009-09-03 2018-04-06 Toray Industries, Inc. Inductor de respuesta inmune
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
JP6255594B2 (ja) * 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
TWI627182B (zh) * 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
CN111925413A (zh) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
ES2856834T3 (es) * 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
EP1007671B1 (de) * 1997-04-07 2002-02-13 Roche Diagnostics GmbH Fanconi-gen ii
DE59803082D1 (en) 1997-04-07 2002-03-21 Roche Diagnostics Gmbh Fanconi-gen ii
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6255055B1 (en) 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030045491A1 (en) * 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2001072775A2 (en) 2000-03-29 2001-10-04 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
WO2002030268A2 (en) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
KR100876327B1 (ko) * 2001-02-21 2008-12-31 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 진단에서의, 그리고 암에서 치료 표적으로서의 ｔｔｋ
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2460283A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Therapeutics and diagnostics for disorders of erythropoiesis
CA2467433A1 (en) 2001-11-13 2003-05-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2005523688A (ja) 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
CN101613406A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
DK2267021T3 (en) * 2002-09-12 2015-03-30 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
ATE505538T1 (de) 2003-06-09 2011-04-15 Corixa Corp Dna-vektoren
WO2005073374A1 (ja) 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原蛋白質及びその利用
JP2005230011A (ja) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2006093337A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
TW200831673A (en) * 2006-12-13 2008-08-01 Oncotherapy Science Inc TTK as tumor marker and therapeutic target for lung cancer
EP2185732A1 (de) * 2007-07-30 2010-05-19 Oncotherapy Science, Inc. Mit krebs assoziiertes gen ly6k
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
JP4461179B2 (ja) 2010-05-12
US8614176B2 (en) 2013-12-24
JP2009173662A (ja) 2009-08-06
JP4493054B2 (ja) 2010-06-30
JP2009173660A (ja) 2009-08-06
PT2325306E (pt) 2014-04-29
WO2006090810A3 (en) 2007-03-29
EP2325306B1 (de) 2014-02-12
US20090202576A1 (en) 2009-08-13
EP1853703A2 (de) 2007-11-14
EP2325305B1 (de) 2014-02-12
EP2325305A1 (de) 2011-05-25
PL2325306T3 (pl) 2014-07-31
PT2325305E (pt) 2014-04-29
JP2010143924A (ja) 2010-07-01
HK1156077A1 (en) 2012-06-01
HK1156076A1 (en) 2012-06-01
WO2006090810A2 (en) 2006-08-31
EP2325306A1 (de) 2011-05-25
JP2008530975A (ja) 2008-08-14
US7847060B2 (en) 2010-12-07
EP1853703B1 (de) 2011-04-13
DK2325306T3 (en) 2014-03-03
ES2459492T3 (es) 2014-05-09
JP4493053B2 (ja) 2010-06-30
DK2325305T3 (en) 2014-03-03
JP2009173661A (ja) 2009-08-06
ES2459466T3 (es) 2014-05-09
ES2364670T3 (es) 2011-09-12
US20110027302A1 (en) 2011-02-03
PL2325305T3 (pl) 2014-07-31

Similar Documents

Publication Publication Date Title
DE602006021283D1 (de) Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert
DK2091965T3 (da) Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
DE602007011923D1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
DK2035447T3 (da) Polypeptid
DK2046826T3 (da) Exendin-fusionsproteiner
ATE451392T1 (de) Gegen amyloid-beta peptid gerichtete antikörper
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
CL2007002783S1 (es) Inhalador multidosis.
DK3118221T3 (da) Proteiner
DK2171053T3 (da) Natriuretiske polypeptider
DE602005023460D1 (de) Antimykotische polypeptide
NO20082488A (no) Pulverblandinger for innhalering
IL189542A0 (en) Proteolysis resistant antibody preparations
BRPI0920428A2 (pt) inalador.
DE602005015131D1 (de) Interleukin-15-antagonistisches peptid
BRPI0814971A2 (pt) Proteína
DK2035451T3 (da) Insulinoptrop peptidsyntese
ATE503759T1 (de) 7-ä2-ä4-(6-fluor-3-methyl-1,2-benzisoxazol-5-yl - 1-piperazinylüethylü-2-(1-propinyl)-7h-pyrazolo
BRPI0814736A2 (pt) inalador.
DK2001518T3 (da) Cykliske natriuretiske peptidfremstillinger
DK2468292T3 (da) Nyt peptid med antisekretorisk aktivitet
DE602005007364D1 (de) Peptidcyclisierung
DK1968623T3 (da) Bacteriocin-inducer-peptider
DK2217619T3 (da) Cyklisk, cystein-frit protein
NO20055451D0 (no) Tunnelovn